Publications

Detailed Information

Nonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study

DC Field Value Language
dc.contributor.authorChoi, Nam-Kyong-
dc.contributor.authorPark, Byung-Joo-
dc.contributor.authorJeong, Sang-Wuk-
dc.contributor.authorYu, Kyung-Ho-
dc.contributor.authorYoon, Byung-Woo-
dc.date.accessioned2010-06-25T07:15:48Z-
dc.date.available2010-06-25T07:15:48Z-
dc.date.issued2008-02-09-
dc.identifier.citationStroke. 2008;39(3):845-859en
dc.identifier.issn1524-4628 (Electronic)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18258834-
dc.identifier.urihttp://stroke.ahajournals.org/cgi/reprint/39/3/845.pdf-
dc.identifier.urihttps://hdl.handle.net/10371/67829-
dc.description.abstractBACKGROUND AND PURPOSE: The relationship between nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and hemorrhagic stroke (HS) remains unclear. We examined the risk of HS associated with the use of NANSAIDs in Koreans. METHODS: We performed a nationwide, multicenter case-control study from 2002 to 2004. This study included 940 nontraumatic acute HS cases in patients aged 30 to 84 years, with an absence of a history of stroke or hemorrhage-prone brain lesions, alongside 940 community controls, matched to each case by age and sex. Pretrained interviewers obtained information on prescription drugs as well as over-the-counter drugs taken within 14 days before the onset of stroke. We adjusted potential confounders, including family histories of stroke, histories of hypertension, smoking, alcohol consumption, high salt intake, and laborious work hours. The adjusted ORs and their 95% CIs were calculated by conditional logistic regression. RESULTS: The proportion of NANSAIDs exposure within 14 days was 2.9% for HS patients and 2.0% for the controls. The adjusted odds ratios of stroke in NANSAIDs users compared with nonusers was 1.12 (95% CI, 0.77 to 1.65) for all HS, 1.03 (95% CI, 0.49 to 2.18) for subarachnoid hemorrhage, and 1.19 (95% CI, 0.76 to 1.87) for intracerebral hemorrhage. CONCLUSIONS: No increased risk of HS either subarachnoid hemorrhage or intracerebral hemorrhage was found among NANSAIDs users.en
dc.description.sponsorshipThis study was partially supported by the Korean Food and Drug
Administration.
en
dc.language.isoenen
dc.publisherAmerican Heart Associationen
dc.subjectAcute Diseaseen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAnti-Inflammatory Agents, Non-Steroidal/*adverse effectsen
dc.subjectAsian Continental Ancestry Groupen
dc.subjectAspirinen
dc.subjectCase-Control Studiesen
dc.subjectCerebral Hemorrhage/*chemically induced/*complicationsen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectOdds Ratioen
dc.subjectRisk Assessmenten
dc.subjectStroke/*etiologyen
dc.subjectSubarachnoid Hemorrhage/chemically induced/complicationsen
dc.titleNonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis studyen
dc.typeArticleen
dc.contributor.AlternativeAuthor최남경-
dc.contributor.AlternativeAuthor박병주-
dc.contributor.AlternativeAuthor정상욱-
dc.contributor.AlternativeAuthor유경호-
dc.contributor.AlternativeAuthor윤병우-
dc.identifier.doi10.1161/STROKEAHA.107.497040-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share